Hospital Admin Articles

Hospital Admin

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Polinski JM et al. - Most MRDD beneficiaries with RA enrolled in Part D. Although plans assume some costs for biologic DMARDs, the majority of costs are shifted to beneficiaries and to Medicare. Such cost shifting may place these medications out of the beneficiary's financial reach and expose Medicare to high financial liability.

Related Articles

Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09    Relevance Score: 71%

Certolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/11/09    Relevance Score: 70%

Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09    Relevance Score: 70%

Treatment of early RA with infliximab is beneficial
American Pharmacists Association, 11/06/09    Relevance Score: 69%

Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09    Relevance Score: 69%

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address